Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Riassunto: Corcept annuncia l'opinione del CHMP che raccomanda l'autorizzazione dell'UE all'immissione in commercio per Lifyorli® (relacorilant)

Friday, September 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Corcept Therapeutics announced that the CHMP has recommended the approval of Lifyorli® (relacorilant) for marketing authorization in the EU. This recommendation is a significant step for Corcept, which focuses on developing treatments for severe endocrine and oncological disorders. The approval could enhance the company's position in the biopharma market.

Market Sentiment Analysis

POSITIVE FACTORS

  • CHMP recommended approval for Lifyorli®.
  • Corcept is advancing its commercial phase.
  • Potential for addressing severe endocrine and oncological conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
3.6%
average across 6 past catalysts
Lead asset
Relacorilant
Phase 2 · Adenocarcinoma

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), un'azienda di fase commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie endocrine, oncologiche, metaboliche e neurologiche attraverso la modulazione degli effetti dell'ormone cortisolo, oggi ha annunciato che il Comitato per i Medicinali per Uso Umano (CHMP) dell’Agenzia europea per i medicinali (EMA) ha raccomandato l'approvazione da parte della Commissione

Frequently Asked Questions

What is Lifyorli®?

Lifyorli® (relacorilant) is a drug developed by Corcept Therapeutics for severe endocrine conditions.

What did the CHMP recommend?

The CHMP recommended the approval of Lifyorli® for marketing authorization in the EU.

Who is Corcept Therapeutics?

Corcept Therapeutics is a commercial-stage company focused on developing treatments for severe endocrine and oncological disorders.

What is the significance of CHMP's recommendation?

The recommendation is a crucial step towards gaining EU approval for Lifyorli®.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare Corcept Lifyorli CHMP relacorilant EMA
Last updated: Sep 18, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RelacorilantPhase 2
Adenocarcinoma →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →